Citi Pharma Limited has decided to proceed with the initial public offering (IPO) of its wholly owned subsidiary, Citi Veterinary Pharma Limited, aiming to raise between Rs1 billion and Rs2 billion from investors.
In a notice of material information submitted to the Pakistan Stock Exchange on March 3, 2026, the company confirmed that its Board of Directors has granted formal approval to initiate the listing process.
To facilitate the transaction, the board has appointed K Trade Securities Limited as Consultant to the Issue, with plans to complete the listing at the earliest feasible date.
Citi Veterinary Pharma has been set up as a specialized entity dedicated to producing veterinary active pharmaceutical ingredients (APIs) and finished pharmaceutical products for the domestic market. The planned IPO reflects Citi Pharma’s broader strategy to expand and strengthen its footprint in the animal health segment, diversifying beyond its core pharmaceutical operations.
The company also indicated that it anticipates generating around Rs1.5 billion in revenue from the trading of veterinary products in fiscal year 2026, underscoring its growth outlook in the livestock and animal healthcare market.
